In 2016, the Partnership to Advance Cardiovascular Health (PACH) launched with the mission of advancing public policies and practices that result in accelerated innovation and improved cardiovascular health for patients around the world.
TAKE ACTION - Sign the Petition Today!
National Association of Insurance Commissioners: Tell Insurance Companies to Quit Playing Games With Our Hearts! Allow Americans Access to Groundbreaking Therapies That Prevent Heart Attacks and Strokes.
Numbers don’t lie. Here are a few examples:
In Alabama, Mississippi and South Carolina, Blue Cross Blue Shield denies patients PCSK9 inhibitors at rates of 61%, 100% and 83% respectively.
In Georgia, Express Scripts and Anthem both deny 73% of patients who seek a PCSK9 inhibitor.
In Kentucky, Anthem denies 72% of patients.
In Michigan, Cigna denies 64% of claims.
As patients wait, the threat of stroke and heart attack looms.
Please sign our petition to call upon the National Association of Insurance Commissioners to fulfill its mission to assist state insurance regulators in serving the public interest. That means raising awareness about the alarming rejection rates that qualifying patients face across the country.
PACH is a 501(c)4 non-profit advocacy organization of diverse stakeholders, including patients, patient advocates, physicians, and scientists. Its goal is to facilitate better cardiovascular health through public policies that:
• Encourage the advancement of cardiovascular science and innovation
• Support the education of patients, health care providers, and other stakeholders
• Facilitate the development of improved means of preventing and treating cardiovascular disease
• Ensure access to appropriate prevention and treatment options for all people
To learn more, connect with PACH via email today.
Heart health complications challenge millions of people worldwide each year. An estimated 102 million Americans have high cholesterol, with more than 35 million of these at high risk for heart disease. Globally, 17.5 million people die of cardiovascular disease annually.
In recent years, innovative advanced medical therapies and medical devices have emerged to offer new treatment options for patients – medications that better control symptoms or reduce side effects that complicate treatment. But health plan coverage has been slow to accommodate breakthrough treatments. Insurers instead have clung to older, less expensive therapies, using restrictive policy design to limit patient access.
Budget-focused policies that assume a one-size-fits-all approach to managing high cholesterol can put patient health at risk. They can also allow cost-cutting tactics to trump physician insight. For patients to benefit from breakthrough treatments for cardiovascular conditions, health policy must support access and decisions about clinical care must continue to take shape within the physician-patient relationship.